Detalles de la búsqueda
1.
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.
Nature
; 616(7957): 553-562, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37055640
2.
The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next-generation sequencing.
Genes Chromosomes Cancer
; 62(10): 589-596, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37222498
3.
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
Breast Cancer Res Treat
; 202(1): 191-201, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37589839
4.
Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.
BMC Cancer
; 22(1): 13, 2022 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34979999
5.
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
Br J Cancer
; 125(12): 1666-1676, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34663950
6.
Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.
Gynecol Oncol
; 163(3): 563-568, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34742578
7.
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.
Br J Cancer
; 122(4): 506-516, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31839677
8.
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 19(7): 975-986, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29880291
9.
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Br J Cancer
; 119(11): 1401-1409, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30353044
10.
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 18(12): 1637-1651, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29103871
11.
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Lancet Oncol
; 17(11): 1579-1589, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27617661
12.
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Lancet Oncol
; 15(8): 852-61, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24882434
13.
Concordance of ATM (ataxia telangiectasia mutated) immunohistochemistry between biopsy or metastatic tumor samples and primary tumors in gastric cancer patients.
Pathobiology
; 80(3): 127-37, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23328638
14.
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
JCO Precis Oncol
; 6: e2100372, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35952319
15.
Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer.
Cancers (Basel)
; 13(22)2021 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-34830984
16.
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.
Nat Med
; 27(5): 793-801, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33941921
17.
Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
Cancer Med
; 10(9): 3045-3058, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33811746
18.
Next-Generation Molecular Residual Disease Assays: Do We Have the Tools to Evaluate Them Properly?
J Clin Oncol
; : JCO2302301, 2024 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38754043
19.
Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors.
Clin Cancer Res
; 23(6): 1471-1480, 2017 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27733477
20.
Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
Oncotarget
; 8(27): 43653-43661, 2017 Jul 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28525389